Epidemiology
Elevated Lp(a) (>=30 mg/dL) more than quadruples risk of adverse cardiac events after PCI in 600 coronary artery disease patients (Indian Heart J 2024)
Original title: Association between Lipoprotein(a) concentration and adverse cardiac events in patients with coronary artery disease: An observational cohort study
In a prospective observational cohort of 600 patients undergoing percutaneous coronary intervention for coronary artery disease (79.16% men), Kaplan-Meier analysis showed significantly higher rates of cardiac death, major adverse cardiac events, myocardial infarction, revascularisation and stroke in patients with Lp(a) >=30 mg/dL. Cox regression identified Lp(a) >=30 mg/dL as an independent risk factor for adverse events (HR 4.2920, 95% CI 2.58-7.120, P<0.05). The findings reinforce Lp(a) as a strong prognostic marker after PCI in an Indian population.
Original abstract
This prospective study investigated the association between lipoprotein (a) [Lp(a)] levels and adverse cardiac events in patients undergoing percutaneous coronary intervention (PCI) for coronary artery disease. Among 600 patients, 79.16 % were male. Kaplan Meier analysis revealed significantly higher incidence rates of cardiac death, major adverse cardiac events, myocardial infarction, revascularization and stroke in patients with elevated Lp(a) (≥30 mg/dL). The Cox Regression model identified Lp(a) ≥30 mg/dL as a significant risk factor for adverse events (HR: 4.2920; 95%CI: 2.58-7.120; p < 0.05). Elevated Lp(a) levels were associated with an increased risk of adverse cardiac events in coronary artery disease patients undergoing PCI.
ancestryepidemiologyrisk prediction
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.